Anticancer drug design using scaffolds of β-lactams, sulfonamides, quinoline, quinoxaline and natural products. Drugs advances in clinical trials

Current Medicinal Chemistry

Volumn 19, Issue 26, 2012, Pages 4377-4398

  Balderas Renteria, I ^a   Gonzalez Barranco, P ^a   Garcia, A ^a   Banik, B K ^b   Rivera, G ^c  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b UNIVERSITY OF TEXAS PAN AMERICAN   (United States)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Cancer; Drugs; Lactams; Natural products; Quinoline; Quinoxaline; Sulfonamide; Targets

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA LACTAM DERIVATIVE; BLEOMYCIN; DACTINOMYCIN; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; MITHRAMYCIN; MITOMYCIN C; NATURAL PRODUCT; NILOTINIB; PROTEIN TYROSINE KINASE; QUINOLINE; QUINOXALINE; SULFONAMIDE; TELOMERASE; TEMSIROLIMUS; VANDETANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DESIGN; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VITRO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; THYROID CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-LACTAMS; BIOLOGICAL AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; QUINOLINES; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84868034853     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803251593     Document Type: Review

References (127)

1. Weiderpass, E. Lifestyle and cancer risk. J. Prev. Med. Public Health., 2010, 43, 459-471.
2. Patel, J.D.; Galsky, M.D.; Chagpar, A.B.; Pyle, D.; Loehrer, P.J. Sr. Role of American Society of Clinical Oncology in low- and middle-income countries. J. Clin. Oncol., 2011, 29, 3097-3102.
3. Seeliger, H.; Guba, M.; Kleespies, A.; Jauch, K.W.; Bruns, C.J. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev., 2007, 26, 611-621.
4. Croce, C.M. Oncogenes and cancer. N. Engl. J. Med., 2008, 358, 502-511.
5. Michor, F.; Iwasa, Y.; Nowak, M.A.; Dynamics of cancer progression. Nat. Rev. Cancer., 2004, 4, 197-205.
6. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer., 2002, 2, 563-572.
7. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumor resistance to apoptosis. Nat. Rev. Cancer., 2002, 2, 277-288.
8. Nowell P. Mechanisms of tumor progression. Cancer Res., 1986, 46, 2203-2207.
9. Sherr, C.J. Principles of tumor suppression. Cell., 2004, 116, 235-246.
10. Gretarsdottir, S.; Thorlacius, S.; Valgardsdottir, R.; Gudlaugsdottir, S.; Sigurdsson, S.; Steinarsdottir, M.; Jonasson, J.G.; Anamthawat-Jonsson, K.; Eyfjord, J.E. BRCA2 and p53 Mutations in Primary Breast Cancer in Relation to Genetic Instability. Cancer Res., 1998, 58, 859-862.
11. Muggia, F.; Safra, T.; Dubeau, L. BRCA genes: lessons learned from experimental and clinical cancer. Ann. Oncol., 2011, 22, i7-i10.
12. Turnbull, C.; Hodgson, S. Genetic predisposition to cancer. Clin. Med., 2005, 5, 491-498.
13. Musolino, A.; Bella, M.A.; Bortesi, B.; Michiara, M.; Naldi, N.; Zanelli, P.; Capelletti, M.; Pezzuolo, D.; Camisa, R.; Savi, M.; Neri, T.M.; Ardizzoni, A. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. B reast., 2007, 16, 280-292.
14. Jefforf, C.E.; Irminger-Finger, I. Mechanisms of chromosome instability in cancers. Crit. Rev. Oncol. Hematol., 2006, 59, 1-14.
15. Beckman, R.A.; Loeb, L.A. Genetic instability in cancer: Theory and experiment. Semin. Cancer Biol., 2005, 15, 423-435.
16. Lee, Y.S.; Dutta, A. MiroRNAs in cancer. Annu. Rev. Pathol., 2009, 4, 199-227.
17. Wang, V.; Wu, W. MicroRNA-based therapeutics for cancer. BioDrugs., 2009, 23, 15-23.
18. Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics., 2009, 1, 239-259.
19. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis., 2010, 31, 27-36.
20. Yim, K.L.; Cunningham, D. Targeted drug therapies and cancer. Recent Results Cancer Res., 2011, 185, 159-171.
21. Demarest, S.J.; Hariharan, K.; Dong, J. Emerging antibody combinations in oncology. MAbs., 2011, 3, 338-351.
22. Komarova, N.L.; Wodarz, D. Drug resistance in cancer: Principles of emergence and prevention. Proc. Natl. Acad. Sci. USA., 2005, 102, 9714-9719.
23. Weis, S.M.; Cheresh, D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 2011, 17, 1359-1370.
24. Mansilla, S.; Llovera, L.; Portugal, J. Chemotherapeutic targeting of cell death pathways. Anticancer Agents Med. Chem., 2012, 12, 226-238.
25. Morris, D.S.; Tomlins, S.A.; Montie, J.E.; Chinnaiyan, A.M. The discovery and application of gene fusions in prostate cancer. BJU Int., 2008, 102, 276-282.
26. Kreitman, R.J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs., 2009, 23, 1-13.
27. Spiekermann, K.; Hiddemann, W. Molekulare zielstrukture in der onkologie. Internist., 2005, 46, 847-860.
28. Shiu, S.H.; Li, W.H. Origins, lineage-specific expansions, and multiple losses of tyrosine kinases in eukaryotes. Mol. Biol. Evol., 2004, 21, 828-840.
29. Eiring, A.M.; Khorashad, J.S.; Morley, K.; Deininger, M.W. Advances in the treatment of chronic myeloid leukemia. BMC Medicine., 2011, 9, 99.
30. Takeuchi, K.; Ito, F. Target Therapy for cancer: Anti-cancer drugs targeting growth-factor signaling molecules. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull., 2011, 34, 1774-1780.
31. Liu, J.C.; Deng, T.; Lehal, R.S.; Kim, J.; Zacksenhaus, E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res., 2007, 67, 8671-8681.
32. Della Peruta, M.; Martinelli, G.; Moratti, E.; Pintani, D.; Vezzalini, M.; Mafficini, A.; Grafone, T.; Iacobucci, I.; Soverini, S.; Murineddu, M.; Vinante, F.; Tecchio, C; Piras, G.; Gabbas, A.; Monne, M.; Sorio, C. Protein tyrosine phosphatase receptor type G is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res., 2010, 70, 8896-8906.
33. Perona, R.; Montaner, S.; Saniger, L.; Sánchez-Pérez, I.; Bravo, R; Lacal, J.C. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev., 1997, 11, 463-475.
34. Kadara, H.; Tahara, E.; Kim, H.J.; Lotan, D.; Myers, J.; Lotan, R Involvement of Rac in fenretinide-induced apoptosis. Cancer Res., 2008, 68, 4416-4423.
35. Pervaiz, S.; Cao, J.; Chao, O.S.; Chin, Y.Y.; Clément, M.V. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene., 2001, 20, 6263-6268.
36. Lingner, J.; Hughes, T.R.; Shevchenko, A.; Mann, M.; Lundblad, V.; Cech, T.R Reverse transcriptase motifs in the catalytic subunit of telomerase. Science., 1997,276, 561-567.
37. Hahn, W.C. Telomere and telomerase dynamics in human cells. Curr. Mol. Med., 2005, 5, 227-231.
38. Bachor, C; Bachor, O.A.; Boukamp, P. Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J. Cancer Res. Clin. Oncol., 1999, 125, 453-460.
39. Nicol, K.W.; Jeffry Evans, T.R.; Glasspool, RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J. Pathol, 2001, 195, 404-414.
40. Olaussen, K.A.; Dubrana, K; Domont, J.; Spano, J.P.; Sabatier, L.; Soria, J.C. Telomeres and telomerase as targets for anticancer drug development. Crit. Rev. Oncol. Hematol., 2006, 57, 191-214.
41. Keith, W.N.; Bilsland, A.; Hardie, M.; Evans, T.R. Drug insight: cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat. Clin. Pract. Oncol., 2004,1, 88-96.
42. Wilke, M.; Lovering, A.; Strynadka, N. [3-Lactam antibiotic resistance: a current structural perspective. Curr. Opin. Microbiol., 2005, 8, 525-533.
43. Williamson, R; Hakenbeck, R; Tomasz, A. In vivo interaction of [3-lactam antibiotics with the penicillin-bin ding proteins of Streptococcus pneunomiae. Antimicrob. Agents Chemother, 1980,18, 629-637.
44. Rodríguez, Z.; Tolón, B.; López, M. Cefalosporinas: métodos de síntesis de modelación molecular. CENIC Ciencias Químicas., 2010, 41, 177-182.
45. Kotra, L.; Mobashery, S. Mechanistic and clinical aspect of [3-lactam antibiotics and [3-lactamases. Arch. Immunol. Ther. Exp., 1999, 47, 211-216.
46. Khun, D.; Coates, C; Daniel, K.; Chen, D.; Bhuiyan, M.; Kazi, A.; Turos, E.; Ping, Q. Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci., 2004, 9, 2605-2617.
47. Vrudhula, V.; Svensson, H.; Kennedy, K.; Senter, P.; Wallace, P. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody- [3-lactamase conjugates. Bioconjugate Chem., 1993, 4, 334-340.
48. Bengang, X.; Jianghong, R; Rongroung, L. Novel Beta-lactam antibiotics derivates: their new applications as gene reporters, antitumor prodrugs and enzyme inhibitors. Mini Rev. Med. Chem., 2008,8, 455-471.
49. Kerr, D.E.; Li, Z.; Siemers, N.O.; Senter, P.D.; Vrudhula, V.M. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjugate Chem., 1998, 9, 255-259.
50. Mehta, P.; Sengar, N.P.S.; Pathak A.K. 2-azetidinone- A new profile of various pharmacological activities. Eur. J. Med. Chem., 2010, 45, 5541-5560.
51. Chen, D.; Falsetti, S.; Frezza, M.; Milacic, V.; Kazi, A.; Cui, Q.; Long, T.; Turos, E.; Dou, Q. Anti-tumor activity of N-thiolated [3-lactam antibiotics. Cancer Lett, 2008,268, 63-69.
52. Kuhn, D.J.; Wang, Y.; Minic, V.; Coates, C; Reddy, G.S.K.; Daniel, K.G.; Shim, J.Y; Chen, D.; Landis-Piwowar, K.R.; Miller, F.R; Turos, E.; Dou, Q.P. Structure-activity relationships of N-methylthiolated beta-lactam antibiotics with C3 substitutions and their selective induction of apoptosis in human cancer cells. Front. Biosci., 2005,10, 1183-1190.
53. Smith, D.M.; Kazi, A.; Smith, L.; Long, T.E.; Heldreth, B.; Turos, E.; Dou, Q.P. A novel [3-lactam antibiotic activates tumor cell apoptotic program by inducing DNA damage. Mol. Pharmacol., 2002, 61, 1348-1358.
54. Kazi, A.; Hill, R.; Long, T.; Kuhn, D.; Turos E.; Dou, Q. Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells. Biochem. Pharmacol, 2004, 67, 365-374
55. Frezza, M.; Garay, J.; Chen, D.; Cui, C; Turos, E.; Dou, Q.P. Induction of tumor cell apoptosis by a novel class of N-thiolated [3-lactam antibiotics with structural modifications at N1 and C3 of the lactam ring. Int. J. Mol. Med, 2008,21, 689-695.
56. Banik, I.; Becker, F.; Banik, B.K. Stereoselective synthesis of beta-lactams with Polyaromatic Imines: Entry to New and novel Anticancer Agents. J. Med. Chem., 2003, 46, 12-15.
57. Watabe, M.; Machida, K.; Osada, H. MT-21 is a synthetic apoptosis inducer that directly induces cytochrome C release from mitochondria. Cancer Res., 2000, 60, 5214-5222.
58. Al-Said, M.S.; Ghorab, M.M.; Al-Dosari, M.S.; Hamed, M.M. Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. Eur. J. Med. Chem., 2011, 46, 201-207.
59. Brzozowski, Z.; Sławiński, J.; Gdaniec, M.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives. Eur. J. Med. Chem., 2011, 46, 4403-4410.
60. Bano, S.; Javed, K.; Ahmad, S.; Rathish, I.G.; Singh, S.; Alam, M.S. Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. Eur. J. Med. Chem., 2011, 46, 5763-5768.
61. Bashir, R; Ovdais, S.; Yaseen, S.; Hamid, H.; Alam, M.S.; Samim, M.; Singh, S.; Javed, K. Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agents. Bioorg. Med. Chem. Lett., 2011,21, 4301-4305.
62. Kamal, A.; Dastagiri, D.; Ramaiah, M.J.; Reddy, J.S.; Bharathi, E.V; Reddy, M.K.; Sagar, M.V; Reddy, T.L.; Pushpavalli, S.N.; Pal-Bhadra, M. Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. Eur. J. Med. Chem., 2011, 46, 5817-5824.
63. Yang, L.; Lei, H.; Mi, C.G.; Liu, H.; Zhou, T.; Zhao, Y.L.; Lai, X.Y; Li, Z.C.; Song, H.; Huang, W.C. Synthesis, antiproliferative activities and in vitro biological evaluation of novel benzofuransulfonamide derivatives. Bioorg. Med. Chem. Lett., 2011,21, 5389-5392.
64. Chen, J.; Liu, T.; Wu, R; Lou, J.; Cao, J.; Dong, X.; Yang, B.; He, Q.; Hu, Y Design, synthesis, and biological evaluation of novel N-γ-carboline aryl-sulfonamides as anticancer agents. Bioorg. Med. Chem., 2010, 18, 8478-8484.
65. Marques, S.M.; Enyedy, E.A.; Supuran, C.T.; Krupenko, N.I.; Krupenko, S.A.; Santos, M.A. Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg. Med. Chem., 2010,18, 5081-5089.
66. El-Sayed, N.S.; El-Bendary, E.R.; El-Ashry, S.M.; El-Kerdawy, M.M. Synthesis and antitumor activity of new sulfonamide derivatives of thiadia-zolo[3,2-a]pyrimidines. Eur. J. Med. Chem., 2011, 46, 3714-20.
67. Carta, F.; Garaj, V; Maresca, A.; Wagner, J.; Avvaru, B.S.; Robbins, A.H.; Scozzafava, A.; McKenna, R; Supuran, C.T. Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies. Bioorg. Med. Chem., 2011, 19, 3105-3119.
68. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; Youssef, H.A.; El-Gazzar, M.G. Synthesis of novel pyrrole and pyrrolo[2,3-d]pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents. Bioorg. Med. Chem. Lett., 2010,20, 6316-6320.
69. Tseng, C.H.; Chen, Y.L.; Lu, P.J.; Yang, C.N.; Tzeng, C.C. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Bioorg. Med. Chem., 2008,16, 3153-3162.
70. Loza-Mejía, M.A.; Olvera-Vázquez, S.; Maldonado- Hernández, K.; Guadar-rama-Salgado, T.; González-Sánchez, I.; Rodríguez-Hernández, F.; Solano, J.D.; Rodríguez- Sotres, R; Lira-Rocha, A. Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives. Bioorg. Med. Chem., 2009,17, 3266-3277.
71. Ai, Y; Liang, Y.J.; Liu, J.C; He, H.W.; Chen, Y; Tang, C; Yang, G.Z.; Fu, L.W. Synthesis and in vitro antiproliferative evaluation of pyrimido[5,4-c]quinoline-4-(3H)-one derivatives. Eur. J. Med. Chem., 2012, 47, 206-213.
72. Lu, CM.; Chen, Y.L.; Chen, H.L.; Chen, C.A.; Lu, P.J.; Yang, C.N.; Tzeng, C.C. Synthesis and antiproliferative evaluation of certain indolo[3,2-c] quinoline derivatives. Bioorg. Med. Chem., 2010,18, 1948-1957.
73. Broch, S.; Aboab, B.; Anizon, F.; Moreau, P. Synthesis and in vitro antiproliferative activities of quinoline derivatives. Eur. J. Med. Chem., 2010, 45, 1657-1662.
74. Weng, Q.; Wang, D.; Guo, P.; Fang, L.; Hu, Y.; He, Q.; Yang, B. Q39, a novel synthetic Quinoxaline 1,4-Di-N-oxide compound with anti-cancer activity in hypoxia. Eur. J. Pharmacol., 2008, 581, 262-269.
75. Das, U.; Pati, H.N.; Panda, A.K.; De Clercq, E.; Balzarini, J.; Molnár, J.; Baráth, Z.; Ocsovszki, I.; Kawase, M.; Zhou, L.; Sakagami, H.; Dimmock, J.R. 2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4- dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance. Bioorg. Med. Chem., 2009,17, 3909-3915.
76. Ismail, M.M.; Amin, K.M.; Noaman, E.; Soliman, D.H.; Ammar, YA. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents. Eur. J. Med. Chem., 2010, 45, 2733-2738.
77. Deleuze-Masquefa, C; Moarbess, G.; Khier, S.; David, N.; Gayraud-Paniagua, S.; Bressolle, F.; Pinguet, F.; Bonnet, P.A. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma. Eur. J. Med. Chem., 2009, 44, 3406-3411.
78. Lee, Y.B.; Gong, YD.; Yoon, H.; Ahn, C.H.; Jeon, M.K.; Kong, J.Y Synthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives. Bioorg. Med. Chem., 2010,18, 7966-7974.
79. Wu, P.; Su, Y; Liu, X.; Zhang, L.; Ye, Y; Xu, J.; Weng, S.; Li, Y; Liu, T.; Huang, S.; Yang, B.; He, Q.; Hu, Y Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3Ka inhibitors. Eur. J. Med. Chem., 2011, 46, 5540-5548
80. Bloch, W.M.; Derwent-Smith, S.M.; Issa, F.; Morris, J.C.; Rendina, L.M.; Sumby, C.J. Fused pyrazino[2,3-b]indolizine and indolizino[2,3-b]quinoxaline derivatives; synthesis, structures and properties. Tetrahedron., 2011, 67, 9368-9375.
81. Noolvi, M.N.; Patel, H.M.; Bhardwaj, V.; Chauhan, A. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. Eur. J. Med. Chem., 2011, 46, 2327-2346.
82. Chen, Q.; Bryant, V.C.; Lopez, H.; Kelly, D.L.; Luo, X.; Natarajan, A. 2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study. Bioorg. Med. Chem Lett., 2011, 21, 1929-1932.
83. Zhao, H.; Donnelly, A.C.; Kusuma, B.R.; Brandt, G.E.L; Brown, D.; Ra-jewski, R.A.; Vielhauer, G.; Holzbeirerlein, J.; Cohen, M.S.; Blagg, B.S.J. Engineering an antibiotic to fight cancer: Optimization of the Novobiocin scaffold to produce anti-proliferative agents. J. Med. Chem., 2011, 54, 3839-3853.
84. Zhao, H.; Kusuma, B.R; Blagg, B.S.J. Synthesis and evaluation of noviose replacements on Novobiocin that manifest antiproliferative activity. Med. Chem. Lett, 2010,1, 311-315.
85. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer., 2009, 9, 28-39
86. Hastings, J.M.; Hadden, M.K.; Blagg, B.S.J. Synthesis and evaluation of Derrubone and select analogues. J. Org. Chem., 2008, 73, 369-373.
87. Baunæk. D.; Trinkler, N.; Ferandin, Y; Lozach, O.; Ploypradith, P.; Rucirawat, S.; Ishibashi, F.; Iwao, M.; Meijer, L. Anticancer alkaloid Lamellarins inhibit protein kinases. Mar. Drugs., 2008, 6, 514-527.
88. Amolins, M.W.; Peterson, L.B.; Blagg, B.S.J. Synthesis and evaluation of electron-rich curcumin analogues. Bioorg. Med. Chem., 2009,17, 360-367.
89. Xu, J.; Chen, A.; Go, M.-L.; Nacro, K.; Liu, B.; Chai, C.L.L. Exploring Aigialomycin D and its analogues as protein kinase inhibitors for cancer targets. Med. Chem. Lett, 2011,2, 662-666.
90. Shengule, S.R; Loa-Kum-Cheung, W.L.; Parish, C.R; Blairvacq, M.; Meijer, L.; Nakao, Y; Karuso, P.A. One-pot synthesis and biological activity of Ageladine A and analogues. J. Med. Chem., 2011, 54, 2492-2503.
91. Chen, Q.-Y; Liu, Y; Luesch, H. Systematic chemical mutagenesis identifies a potent novel Apratoxin A-E hybrid with improved in vivo antitumor activity. Med. Chem. Lett, 2011, 2, 861-865.
92. Siles, R; Ackley, J.F.; Hadimani, M.B.; Hall, J.J.; Mugabe, B.E.; Guddnep-panavar, R; Monk, K.A.; Chapuis, J.C.; Pettit, G.R; Chaplin, D.J.; Edvardsen, K.; Trawick, M.L.; Garner, CM; Pinney, K.G. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents. J. Nat. Prod., 2008, 71, 313-320.
93. Takeuchi, T.; Oishi, S.; Watanabe, T.; Ohno, H.; Sawada, J.I.; Matsuno, K.; Asai, A.; Asada, N.; Kitaura, K; Fujii, N. Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors. J. Med. Chem., 2011, 54, 4839-4846.
94. Singh, A.J.; Razzak, M.; Teesdale-Spittle, P.; Gaitanos, T.N.; Wilmes, A.; Paterson, I.; Goodman, J.M.; Miller, J.H.; Northcote, P.T. Structure-activity studies of the pelorusides: new congeners and semi-synthetic analogues. Org. Biomol. Chem., 2011, 9, 4456-4466.
95. Pfeiffer, B.; Hauensteins, K.; Merz, P.; Gertsch, J.; Altmann, K.H. Synthesis and SAR of C12-C13-oxazoline derivatives of epothilone A. Bioorg. Med. Chem., 2009,19, 3760-3763.
96. Balasubramanian, R.; Raghavan, B.; Begaye, A.; Sackett, dan L.; Fecik, R.A. Total synthesis and biological evaluation of Tubulysin U, Tubulysin V, and their analogues. J. Med. chem., 2009, 52, 238-240.
97. Wyche, T.P.; Hou, Y.; Braun, D.; Cohen, H.C.; Xiong, M.P.; Bugni, T.S. First natural analogs of the cytotoxic thiodepsipeptide Thiocoraline A from a marine Verrucosispora sp. J. Org. Chem., 2011, 76, 6542-6547.
98. Bitzer, J.; Streibel, M.; Langer, H.J.; Grond, S. First Y-type actinomycins from Streptomyces with divergent structure-activity relationships for antibacterial and cytotoxic properties. Org. Biomol. Chem., 2009, 7, 444-450.
99. http://www.fda.gov/ Accessed January 21, 2012.
100. ClinicalTrials.gov. http://www.clinicaltrial.gov Accessed January 21, 2012.
101. Baas, P.; Szczesna, A.; Albert, I.; Milanowski, J.; Juhász, J.; Sztancsik, Z.; Von Pawel, J.; Oyama, R.; Buergers, S. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 745-750.
102. Shionoya, M.; Jimbo, T.; Kitagawa, M.; Soga, T.; Tohgo, A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci., 2003, 94, 459-466.
103. Vora, T.; Azambuja, E.; Awada, A.; Piccart, M. Novel therapeutics in breast cancer - looking to the future. Update Cancer Ther., 2009, 3, 189-205.
104. Diéras, V.; Limentani, S.; Romieu, G.; Tubiana-Hulin, M.; Lortholary, A.; Kaufman, P.; Girre, V.; Besenval, M.; Valero, V. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol., 2008, 19, 1255-1260.
105. Pivot, X.; Koralewski, P.; Hidalgo, J.L.; Chan, A.; Gonçalves, A.; Schwartsmann, G.; Assadourian, S.; Lotz, J.P. A multicenter phase II study of WRP6258 administered as a 1-h in vivo infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol., 2008, 19, 1547-1552.
106. Fleming, M.; Sonpavde, G.; Kondagunta, V.; Galsky, M.; Hutson, T.; Stern-berg, C. Systemic therapy and novel agents for metastatic castration resistant prostate cancer. Update Cancer Ther., 2009, 3, 133-143.
107. Mulzer, J.; Altmann, K.H.; Höfle, G.; Müller, R.; Prantz, K. Epothilones - A fascinating family of microtubule stabilizind antitumor agents. C. R. Chimie., 2008, 11, 1336-1368.
108. Hennessy, B.T.; Markman, M. Development of novel agents for ovarian cancer. Update Cancer Ther., 2009, 3, 119-132.
109. Liang, H.; Tan, A.R. PARP inhibitors. Curr. Breast Cancer Rep., 2011, 3, 44-54.
110. Kummar, S.; Kinders, R.; Gutierrez, M.E.; Rubinstein, L.; Parchment, R.E.; Philips, L.R.; Ju, J.; Monks, A.; Low, J.A.; Chen, A.; Murgo, A.J.; Collins, J.; Steinberg, S.M.; Eliopoulos, H.; Giranda, V.L.; Gordon, G.; Helman, L.; Wiltrout, R.; Tomaszewski, J.E.; Doroshow, J.H. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in patients with Advanced Malignancies. J. Clinic. Onc., 2009, 27, 2705-2711.
111. Abair, T.; Peck, S. Highlights from. The 2009 annual meeting of the American Society of Clinical Oncology. Clinic. Breast Cancer., 2009, 9, 140-144
112. Powell, C.; Mikropoulos, C.; Kaye, S.B.; Nutting, C.N.M.; Newbold, K.; Harrington, K.J. Pre-clinical and clinical evaluation of PARP inhibitors as tumour specific radiosensitisers. Cancer Treat. Rev., 2010, 36, 566-575.
113. Kaye, S.B.; Lubinski J.; Matulonis, U.; Ang, J.E.; Gourley, C., Karlan, B.Y.; Amnon, A.; Bell-Mcguinn, K.M.; Chen, L.; Friedlander, M.; Safra, T.; Vergote, I.; Wickens, M.; Lowe, E.S.; Carmichael, J.; Kaufman, B. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. J. Clinic. Onc., 2012, 30, 372-379.
114. London, C.A.; Bear, M.D.; McCleese, J.; Foley, K.P.; Paalangara, R.; Inoue, T.; Ying, W.; Barsoum, J. Phase I evaluation of STA-1474, a product of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. Plos One., 2011, 6, 1-10.
115. Brown, R.; Cohen, E. Novel approaches in the treatment of thyroid cancer. Update Cancer Ther., 2008, 3, 1-11.
116. Ramanathan, R.K.; Egorin, M.J.; Erlichman, C.; Remick, S.C.; Ramalingam, S.S.; Naret, C.; Holleran, J.L.; TenEyck, C.J.; Ivy, S.P.; Belani, C.P. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17- demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors. J. Clin. Onc., 2010, 28, 1520-1526
117. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351, 95-105.
118. Meric-Bernstam, F; Gonzalez-Angulo, A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Onc., 2009, 27, 2278-2287.
119. Galsky, M.; Sonpavde, G.; Kapil, R.; Fleming, M.; Kondagunta, G.V.; Hutson, T.E.; Sternberg, C. Development of novel agents and combinations for renal carcinoma. Update Cancer Ther., 2008, 3, 97-103.
120. Fouladi, M.; Stewart, C.F.; Blaney, S.M.; Onar-Thomas, A.; Schaiquevich, P.; Packer, R.J.; Gajjar, A.; Kun, L.E.; Boyett, J.M.; Gilbertson, R.J. Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. J. Clin. Onc., 2010, 28, 4221-4227.
121. National Cancer Institute at the National Institutes of Health. Clinical Trials. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid= 100726 33. Accessed January 19, 2012.
122. Jansen, M.H.A.; Van Vuurden, D.G.; Vandertop, W.P.; Kaspers, G.J.L. Diffuse intrinsec pontine gliomas: A systematic update on clinical trials and biology. Cancer Treat. Rev., 2012, 38, 27-35.
123. Ryan, C.J.; Smith, M.R.; Fong, L.; Rosenberg, J.E.; Kantoff, P.; Raynaud, F.; Martins, V.; Lee, G.; Kheoh, T.; Kim, J.; Molina, A.; Small, E.J. Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy. J. Clin. Onc., 2010, 28, 1481-1488.
124. Warren, K.E.; Goldman, S.; Pollack, I.F.; Fangusaro, J.; Schaiquevich, P.; Stewart, C.F.; Wallace, D.; Blaney, S.M.; Packer, R.; MacDonald, T.; Jakacki, R.; Boyett, J.M.; Kun, L.E. Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J. Clin. Onc., 2011, 29, 324-329.
125. Sweeney, C.J.; Chiorean, E.G.; Verschraegen, C.F.; Lee, F.C.; Jones, S.; Royce, M.; Tye, L.; Liau, K.F.; Bello, A.; Chao, R.; Burris, H.A. A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. J. Clin. Onc., 2010, 28, 4513-4520.
126. Gandhi, L.; Camidge, D.R.; de Oliveira, M.R.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, C.L.; McKeegan, E.M.; Litvinovich, E.; Hemken, P.M.; Dive, C.; Enschede, S.H.; Nolan, C.; Chiu, Y.; Busman, T.; Xiong, H.; Krivoshik, A.P.; Humerickhouse, R.; Shapiro, G.I.; Rudin, C.M. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. J. Clin. Onc., 2011, 29, 909-916.
127. Fouladi, M.; Stewart, C.F.; Olson, J.; Wagner, L.M.; Onar-Thomas, A.; Kocak, M.; Packer, R.J.; Goldman, S.; Gururangan, S.; Gajjar, A.; Demuth, T.; Kun, L.E.; Boyett, J.M.; Gilbertson, R.J. Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. J. Clin. Onc., 2011, 29, 3529-3534.